The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium.
Devraj SukulMilan SethTheodore SchreiberAkshay KhandelwalLouis A CannonThomas A LaLondeHitinder S GurmPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2017)
We found no significant differences in in-hospital outcomes between bivalirudin and UFH monotherapy among dialysis patients undergoing PCI. Randomized clinical trials are needed to determine the optimal anticoagulant regimen for this population. © 2017 Wiley Periodicals, Inc.
Keyphrases
- percutaneous coronary intervention
- end stage renal disease
- chronic kidney disease
- peritoneal dialysis
- st segment elevation myocardial infarction
- acute coronary syndrome
- acute myocardial infarction
- st elevation myocardial infarction
- coronary artery disease
- antiplatelet therapy
- patients undergoing
- atrial fibrillation
- coronary artery bypass grafting
- ejection fraction
- randomized controlled trial
- combination therapy
- venous thromboembolism
- newly diagnosed
- systematic review
- healthcare
- open label
- emergency department
- prognostic factors
- growth factor
- metabolic syndrome
- skeletal muscle
- light emitting